Sondhi Arun, Garrett Tina
Therapeutic Solutions (Addictions) Limited, London, UK.
Department of Health and Wellbeing, Public Health England South Region, Bristol, UK.
Int J Prison Health. 2018 Dec 17;14(4):268-275. doi: 10.1108/IJPH-11-2017-0052.
Prisoner access to opiate-based analgesics and gabapentinoids is a concern to prisons through illicit trading. The purpose of this paper is to describe patient needs following introduction of nine pilot chronic non-cancer pain (CNCP) clinics for chronic pain in three prisons (two male and one female) in the South of England. The study evaluated the effectiveness of this model and assessed the wider practical implementation issues.
DESIGN/METHODOLOGY/APPROACH: Clinical notes were reviewed for 63 consultations, anonymised and recorded for secondary analysis.
Alongside CNCP, high levels of substance misuse, physical and mental health histories were noted, especially for female patients. Amitriptyline, pregabalin, gabapentin were the main frontline analgesics prescribed prior to assessment. A total of 41 per cent of patients did not change their medication following the consultation; 25 per cent had their medication increased or reintroduced (greater for women prisoners); with one-third (33 per cent) of patients reducing the prescription of strong opioids and gabapentinoids. Significant differences were noted between male and female patients. Prisoners were amenable to changes in medication to facilitate access to work and other therapeutic interventions.
The prescribing of analgesics has largely been couched in terms of disruption to the prison regime through illicit trading. This study highlights the need to place CNCP within wider contexts of substance misuse, physical and emotional health. There is an opportunity to develop a rehabilitative rather than palliative approach to pain management. Gender specific approaches for female patients should be considered.
ORIGINALITY/VALUE: Few studies of CNCP have been conducted within a prison environment.
囚犯通过非法交易获取阿片类镇痛药和加巴喷丁类药物是监狱关注的问题。本文旨在描述在英格兰南部的三所监狱(两所男性监狱和一所女性监狱)引入九个慢性非癌性疼痛(CNCP)试点诊所治疗慢性疼痛后患者的需求。该研究评估了该模式的有效性,并评估了更广泛的实际实施问题。
设计/方法/途径:对63次会诊的临床记录进行了审查,进行匿名处理并记录下来以供二次分析。
除了CNCP外,还注意到药物滥用、身体和心理健康史的高水平,尤其是女性患者。阿米替林、普瑞巴林、加巴喷丁是评估前主要开具的一线镇痛药。共有41%的患者在会诊后未改变用药;25%的患者增加了用药剂量或重新开始用药(女性囚犯增加的比例更高);三分之一(33%)的患者减少了强效阿片类药物和加巴喷丁类药物的处方。男性和女性患者之间存在显著差异。囚犯愿意改变用药以便能够工作和接受其他治疗干预。
镇痛药的处方很大程度上是基于非法交易对监狱管理制度的干扰。本研究强调需要将CNCP置于药物滥用、身体和情感健康的更广泛背景中。有机会制定一种康复而非姑息的疼痛管理方法。应考虑针对女性患者的性别特定方法。
原创性/价值:很少有在监狱环境中进行的CNCP研究。